Livan Delgado-Roche

Dr. Livan Delgado-Roche

orcid

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 January 2021 in Marine Drugs
Verified
Journal Article
Open access
PDF file
Ivones Hernández BalmasedaIvones Hernández Balmaseda
Ivones Hernández Balmaseda
IRIdania Rodeiro
Idania Rodeiro
KDKen Declerck
Ken Declerck
JHJose Alfredo Herrera
Jose Alfredo Herrera
CNClaudina Perez Novo
Claudina Perez Novo
WBWim Vanden Berghe
Wim Vanden Berghe
Marine plants have become an inexhaustible reservoir of new phytopharmaceuticals for cancer treatment. We demonstrate in vitro/in vivo antitumor efficacy of a standardized polyphenol extract from the marine angiosperm Thalassia testudinum (TTE) in colon tumor cell lines (RKO, SW480, and CT26) and a syngeneic allograft murine colorectal cancer model. MTT assays revealed a dose-dependent decrease of cell viability of RKO, CT26, and SW480 cells upon TTE treatment with IC50 values of, respectively, 175, 115, and 60 μg/mL. Furthermore, TTE significantly prevented basal and bFGF-induced angiogenesis in the chicken chorioallantoic membrane angiogenesis assay. In addition, TTE suppressed bFGF-induced migration of endothelial cells in a wound closure assay. Finally, TTE treatment abrogated CT26 colorectal cancer growth and increased overall organism survival in a syngeneic murine allograft model. Corresponding transcriptome profiling and pathway analysis allowed for the identification of the mechanism of action for the antitumor effects of TTE. In line with our in vitro/in vivo results, TTE treatment triggers ATF4-P53-NFκB specific gene expression and autophagy stress pathways. This results in suppression of colon cancer cell growth, cell motility, and angiogenesis pathways in vitro and in addition promotes antitumor immunogenic cell death in vivo.

6 February 2019 in Phytotherapy Research
Verified
Journal Article
Closed access
PDF file
LDLivan Delgado-Roche
Livan Delgado-Roche
IRIdania Rodeiro
Idania Rodeiro
MRMario Riera
Mario Riera
JHJosé Alfredo Herrera
José Alfredo Herrera
IVIvonilce Venturi
Ivonilce Venturi
MLMiriam Lopes
Miriam Lopes

26 February 2013 in Free Radical Research
Verified
Journal Article
Closed access
LDLivan Delgado-Roche
Livan Delgado-Roche
EAE. Acosta
E. Acosta
YSY. Soto
Y. Soto
YHY. Hernández-Matos
Y. Hernández-Matos
AOA. Olivera
A. Olivera
AVA. M. Vázquez
A. M. Vázquez
Retained low-density lipoproteins (LDL) by arterial glycosaminoglycans (GAG) are more susceptible to reactive oxygen species-mediated oxidation, contributing to oxidative stress and atherosclerosis. Recently, we reported the properties of the chimeric mouse/human monoclonal antibody chP3R99-LALA to bind sulfated GAG, to inhibit LDL-chondroitin sulfate binding, and to avoid LDL oxidation in vitro. Here, we hypothesized that chP3R99-LALA treatment might reduce aortic oxidative stress in a therapeutic setting. Redox biomarkers and serum lipids were determined by spectrophotometric methods. Subcutaneous administration of five doses (100 μg) of chP3R99-LALA, after Lipofundin administration (2 mL/kg/day, i.v.) during 8 days, reduced atherosclerotic lesion development, which was not associated with a serum lipid modulation. In contrast, the treatment with chP3R99-LALA reduced (p < 0.05) malondialdehyde and protein oxidation, induced a restoration of reduced glutathione level, of the superoxide dismutase and catalase activities and of endothelial nitric oxide level. Thus, the antiatherogenic effect of chP3R99-LALA treatment seems to be associated with a reduction of aortic oxidative stress. These results contribute in understanding the molecular mechanisms associated with chP3R99-LALA atheroprotection and support the use of anti-GAG antibody-based immunotherapy as a potential tool to treat the atherosclerosis.

19 November 2020 in Marine Drugs
Verified
Journal Article
Open access
PDF file
LDLivan Delgado-Roche
Livan Delgado-Roche
RSRebeca Santes-Palacios
Rebeca Santes-Palacios
JHJosé A. Herrera
José A. Herrera
SHSandra L. Hernández
Sandra L. Hernández
MRMario Riera
Mario Riera
JEJavier Jesús Espinosa-Aguirre
Javier Jesús Espinosa-Aguirre
The aim of the present work was to evaluate the effects of Thalassia testudinum hydroethanolic extract, its polyphenolic fraction and thalassiolin B on the activity of phase I metabolizing enzymes as well as their antimutagenic effects. Spectrofluorometric techniques were used to evaluate the effect of tested products on rat and human CYP1A and CYP2B activity. The antimutagenic effect of tested products was evaluated in benzo[a]pyrene (BP)-induced mutagenicity assay by an Ames test. Finally, the antimutagenic effect of Thalassia testudinum (100 mg/kg) was assessed in BP-induced mutagenesis in mice. The tested products significantly (p < 0.05) inhibit rat CYP1A1 activity, acting as mixed-type inhibitors of rat CYP1A1 (Ki = 54.16 ± 9.09 μg/mL, 5.96 ± 1.55 μg/mL and 3.05 ± 0.89 μg/mL, respectively). Inhibition of human CYP1A1 was also observed (Ki = 197.1 ± 63.40 μg/mL and 203.10 ± 17.29 μg/mL for the polyphenolic fraction and for thalassiolin B, respectively). In addition, the evaluated products significantly inhibit (p < 0.05) BP-induced mutagenicity in vitro. Furthermore, oral doses of Thalassia testudinum (100 mg/kg) significantly reduced (p < 0.05) the BP-induced micronuclei and oxidative damage, together with an increase of reduced glutathione, in mice. In summary, Thalassia testudinum metabolites exhibit antigenotoxic activity mediated, at least, by the inhibition of CYP1A1-mediated BP biotransformation, arresting the oxidative and mutagenic damage. Thus, the metabolites of T. testudinum may represent a potential source of chemopreventive compounds for the adjuvant therapy of cancer.

1 January 2018 in Journal of Pharmacy & Pharmacognosy Research
Verified
Journal Article
Closed access
CGCaridad M. García
Caridad M. García
MFMirna Fernández
Mirna Fernández
OLOrestes D. López
Orestes D. López
LDLivan Delgado-Roche
Livan Delgado-Roche
ANAntonio Nogueira
Antonio Nogueira
EMEsteban A. Medrano
Esteban A. Medrano
Context: Spray-drying is a technique used to produce encapsulated products, thus improving the stability of components as well as their organoleptic characteristics. Aims: To evaluate the effect of microencapsulation of shark liver oil pool by spray drying on its physical-chemical properties and antioxidant capacity. Methods: A mix design was created with a constant load of oil, made possible by controlling the proportion between chitosan acetate and maltodextrin. Loss on drying, encapsulation efficiency and yield were determined for the microcapsules. Reversed-phase HPLC analysis was used in order to determine the vitamin A content in microencapsulated and non-microencapsulated oil, as well as its delivery from the dried product. Vitamin A was the active compound used as a chemical marker. The following parameters were also evaluated: organoleptic characteristics, moisture content, particle size, surface morphology and antioxidant capacity. Results: The encapsulation efficiency of microencapsulated oil increased slightly as the concentration of chitosan acetate increased. In order to achieve a greater encapsulation efficiency and a lower moisture content in microencapsulated oil, the proportion between chitosan acetate and maltodextrin should be maintained at 35% and 35% each, according to established manufacturing conditions. Both polymers prevent oil from leaving the droplet. This is a very important factor in storage stability of vitamins and fatty acids, which are subject to oxidative deterioration. Conclusions: Spray-drying microencapsulation of pool oil does not affect vitamin A content or delivery; fatty acid content and antioxidant capacity are also not affected.

Verified
Journal Article
Open access
PDF file
TSTania A. Sibaja
Tania A. Sibaja
GEGuadalupe A. Espinoza
Guadalupe A. Espinoza
YDYazmin I. Dávila
Yazmin I. Dávila
ESErick M. Salinas
Erick M. Salinas
JVJuan J. Venegas
Juan J. Venegas
LDLivan Delgado-Roche
Livan Delgado-Roche
Objectives: The aim of the present study was to evaluate the efficacy and safety of etoricoxib–tramadol 120 mg/100 mg (Eto-Tr) in acute moderate-to-severe pain. Methods: Eto-Tr once a day (n = 29) or naproxen 220 mg + tramadol 50 mg (Nap-Tr) every 12 h (n = 28) were administered after a third molar extraction for three days. Pain intensity difference at 4 h (PID4) was determined as the primary outcome. In addition, total pain relief (TOTPAR), trismus control, and adverse events were addressed. Results: The population PID4 score was 0 mm (Nap-Tr IQR 13 mm; Eto-Tr IQR 35 mm; p = 0.182). No differences for PID scores were observed (1 h to 72 h). TOTPAR increased gradually from 35.71% (Nap-Tr) and 39.39% (Eto-Tr) at 4 h to 67.86% (Nap-Tr) and 58.62% (Eto-Tr) at 72 h. Sustained pain relief over time and clinically meaningful trismus reduction was also observed (Nap-Tr: 4 mm [IQR 28.10] vs. Eto-Tr: 9.8 mm [IQR 12.3], p = 0.175). Common adverse events were notified [Nap-Tr (n = 5, 19%); Eto-Tr (n = 8, 27%)]. Conclusions: The once-daily administration of Eto-Tr 120 mg/100 mg showed similar efficacy and safety to conventional treatment in moderate-to-severe acute pain. The once-daily regimen together with a multimodal analgesia represents a suitable patient-centered alternative for pain management.